Immunology, Parasitology, Applied Microbiology and Biotechnology
137
Scopus Publications
Scopus Publications
Development of a 17-DMAG-Loaded Carboxymethylcellulose Gel for In Vivo Treatment of Cutaneous Leishmaniasis Kercia Pinheiro Cruz, Mariana Rolemberg Gueudeville Silveira, Igor Rolemberg Gueudeville Silveira, Jade Liz Ferreira Mendes Souza, Marina Faillace De Amorim, Alan Gualberto De Souza De Freitas De Pinho, Ana Luiza de Jesus Cordeiro, Izabella Gouveia Oliveira, Isadora dos Santos Lima, Claudia Ida Brodskyn, Juliana Perrone Bezerra de Menezes, Deborah Bittencourt Motte, Henrique Rodrigues Marcelino, Fabio Rocha Formiga, Washington Luis Conrado dos Santos, Thamires Quadros Froes, Patricia Sampaio Tavares Veras ACS Omega, 2026 Cutaneous leishmaniasis (CL) is a neglected tropical disease for which safer and more effective therapeutic options are urgently needed. Heat shock protein 90 (Hsp90) inhibitors have emerged as promising antileishmanial agents. Among geldanamycin derivatives, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) has previously demonstrated potent activity against Leishmania braziliensis. Here, we evaluated the therapeutic potential of a topical 17-DMAG formulation for CL. The compound exhibited low cytotoxicity toward human keratinocytes (HaCaT) and THP-1 macrophages cell-lines. A carboxymethylcellulose (CMC) hydrogel containing 17-DMAG showed physicochemical stability for up to 90 days at 4 and 25 °C, with diffusion-controlled drug release. In BALB/c mice infected with L. braziliensis, topical treatment induced mild and transient local inflammation, without systemic toxicity. Notably, the 0.10 mg/g formulation reduced lesion size by up to 47% and achieved 80% complete healing by week 3. These findings support topical 17-DMAG formulation as a safe, effective, and noninvasive therapeutic approach for experimental CL.
Performance of Three Commercial Rapid Diagnostic Tests for Detection of IgM and IgG Antibodies Against SARS-CoV-2 Moyra Machado Portilho, Stephane Fraga de Oliveira Tosta, Maysa Pellizzaro, Rosângela Oliveira dos Anjos, Elaine Carvalho de Oliveira, Pamela dos Santos Nascimento de Santana, Patrícia Sousa dos Santos Moreira, Leile Camila Jacob‐Nascimento, Mirela Maisa da Silva Souza, Deborah Bittencourt Mothé, Cláudia Brodskyn, Mitermayer Galvão Reis, Cristiane Wanderley Cardoso, Guilherme Sousa Ribeiro Immunity Inflammation and Disease, 2026 Background Despite widespread vaccination, SARS‐CoV‐2 transmission continues, and serological testing remains relevant for selected diagnostic scenarios and population‐based assessments of antibody responses. Rapid diagnostic tests (RDTs) for SARS‐CoV‐2 antibodies are attractive for field use and decentralized settings, but their diagnostic performance varies and requires independent evaluation. We assessed the performance of three commercially available lateral flow RDTs (PANBIO™ COVID‐19 IgG/IgM Rapid Test Device, Bio‐Manguinhos‐Fiocruz TR COVID‐19 (IgM‐IgG), and Bio‐Manguinhos‐Fiocruz TR DPP® COVID‐19 IgM/IgG) in Salvador, Brazil. Methods Using blind analyses, we evaluated 257 serum samples from RT‐PCR‐confirmed cases and 199 control samples from individuals with other febrile illnesses or healthy donors collected before and during the pandemic. Results Overall sensitivity for IgM or IgG detection was limited across all tests (52%–58%), while specificity was high for two assays (97%–98%) and lower for one (80%). Sensitivity peaked between 11 and 20 days after symptom onset (80%–91%) and declined thereafter. Among 75 vaccinated individuals without prior COVID‐19, antibody positivity ranged from 39% to 55%. Conclusion These findings indicate that the evaluated RDTs had high specificity but insufficient sensitivity for reliable clinical diagnosis or for assessing vaccination status in serological surveys. Our results support cautious use of these assays and highlight the need for more accurate and robust antibody‐based rapid tests to strengthen immunological surveillance and public health preparedness in the post‐pandemic period.
Oral Treatment With Heat Shock Protein 65-Producing Lactococcus lactis Induces Regulatory T Cells, Modulating Inflammatory Response in Leishmania braziliensis Infection Camila Mattos Andrade, Ítalo da Silva Gonçalves, Maria Luiza das Neves Nascimento, Washington Luís Conrado Santos, Vasco Ariston Azevedo, Deborah Bittencourt Mothé, Juliana Perrone Menezes Fullam, Patrícia Sampaio Tavares Veras, Natalia Machado Tavares, Tatiani Uceli Maioli, Ana Maria Caetano Faria, Cláudia Ida Brodskyn Immunology, 2026 Cutaneous leishmaniasis (CL), a neglected tropical disease prevalent in Brazil, is caused by Leishmania braziliensis (L. braziliensis) and is marked by ulcerative skin lesions and an exacerbated Th1‐driven inflammatory response. This study investigates the therapeutic potential of oral tolerance (OT) induced by a genetically modified strain of Lactococcus lactis (L. lactis) producing heat shock protein 65 (HSP65) from Mycobacterium leprae in a murine model of CL. BALB/c mice were infected with L. braziliensis and treated orally with HSP65‐producing L. lactis or control L. lactis (empty vector) for four consecutive days, starting at 4 weeks post‐infection. Mice receiving HSP65‐producing L. lactis showed reduced lesion size and parasite burden. Cytokine analysis in draining lymph nodes revealed a shift from a pro‐inflammatory IFN‐γ response to an increased IL‐10 production, correlating with milder inflammation and less tissue damage. Additionally, the treatment promoted an increase in regulatory T cells (Tregs), including CD4+CD25+FOXP3+ and CD4+LAP+ (membrane‐associated TGF‐β) cells in the draining lymph nodes. This therapeutic effect was not observed in a more severe model of CL using Leishmania major. This study underscores the potential of oral tolerance induction using HSP65‐producing L. lactis as a promising immunoregulatory therapeutic approach for some chronic inflammatory infections, mainly those that display a primed balance in immune response.
Recent advances in the development and clinical application of miRNAs in infectious diseases Sara Nunes, Rana Bastos, Ananda Isis Marinho, Raissa Vieira, Ingra Benício, Maria Alícia de Noronha, Sofia Lírio, Cláudia Brodskyn, Natalia Machado Tavares Non Coding RNA Research, 2025 In the search for new biomarkers and therapeutic targets for infectious diseases, several molecules have been investigated. Small RNAs, known as microRNAs (miRs), are important regulators of gene expression, and have emerged as promising candidates for these purposes. MiRs are a class of small, endogenous non-coding RNAs that play critical roles in several human diseases, including host-pathogen interaction mechanisms. Recently, miRs signatures have been reported in different infectious diseases, opening new perspectives for molecular diagnosis and therapy. MiR profiles can discriminate between healthy individuals and patients, as well as distinguish different disease stages. Furthermore, the possibility of assessing miRs in biological fluids, such as serum and whole blood, renders these molecules feasible for the development of new non-invasive diagnostic and prognostic tools. In this manuscript, we will comprehensively describe miRs as biomarkers and therapeutic targets in infectious diseases and explore how they can contribute to the advance of existing and new tools. Additionally, we will discuss different miR analysis platforms to understand the obstacles and advances of this molecular approach and propose their potential clinical applications and contributions to public health.
High glucose heightens vulnerability to Leishmania braziliensis infection in human macrophages by hampering the production of reactive oxygen species through TLR2 and TLR4 Ícaro Bonyek-Silva, Rana Bastos, Sara Nunes, Rafael Tibúrcio, Alexsandro Lago, Juliana Silva, Lucas P. Carvalho, Ricardo Khouri, Sergio M. Arruda, Aldina Barral, Viviane Boaventura, Henrique C. Serezani, Edgar M. Carvalho, Cláudia Ida Brodskyn, Natalia Machado Tavares Emerging Microbes and Infections, 2025 Diabetes increases susceptibility to infections, including Leishmania braziliensis (Lb). Our group previously demonstrated that diabetic patients with cutaneous leishmaniasis (CL) take longer to heal lesions compared to non-diabetics. Since macrophages play a critical role in CL pathogenesis, we investigated how high glucose levels impact their response during Lb infection. Macrophages cultured in high glucose conditions showed increased parasite load than those in normal glucose conditions. The production of inflammatory mediators was similar between glucose conditions, but basal reactive oxygen species (ROS) production was elevated under high glucose conditions and remained unchanged after Lb infection, indicating glucose-induced oxidative stress does not control the parasite. In contrast, macrophages in normal glucose conditions, exhibited increased ROS production only after infection. Additionally, high glucose reduced TLR2 and TLR4 expression, which was also observed after Lb infection. TLR2/4 inhibition increased Lb infection in normal glucose conditions, mediated by TLR-dependent ROS production. However, this mechanism was absent under high glucose conditions, where elevated basal ROS production appeared TLR-independent. Biopsies from diabetic CL patients corroborated these findings, showing decreased TLR2 and TLR4 expression compared to non-diabetics. These findings suggest that high glucose levels induce oxidative stress and reduces TLR expression, impairing macrophage functions and rendering them less effective at controlling Lb infection.
Pharmacological inhibition of key metabolic pathways attenuates Leishmania spp infection in macrophages Elaine Carvalho de Oliveira, Rafael Tibúrcio, Gabriela Duarte, Amanda Lago, Léon de Melo, Sara Nunes, Gustavo Gastão Davanzo, Ana Júlia Martins, Bruno Vinagre Ribeiro, Deborah Mothé, Juliana B. P. Menezes, Patrícia Veras, Natalia Tavares, Pedro M. Moraes-Vieira, Cláudia Ida Brodskyn Plos Neglected Tropical Diseases, 2025 Macrophages represent a fundamental component of the innate immune system that play a critical role in detecting and responding to pathogens as well as danger signals. Leishmania spp. infections lead to a notable alteration in macrophage metabolism, whereby infected cells display heightened energy metabolism that is linked to the integrity of host mitochondria. However, little is known about how different species of Leishmania manipulate host metabolism. Here, we demonstrate that despite differences in their mechanisms for evading host immune responses, L. amazonensis and L. braziliensis induce comparable disruptions in key metabolic pathways. We found that infected macrophages exhibited an overall elevation in energy metabolism regardless of the parasite strain, evidenced by the elevation in glycolysis and oxygen consumption rates, along with increased proton leak and decreased ATP production. We also analyzed the effects of both Leishmania spp. strain infection on mitochondria function, further revealing that infected cells display heightened mitochondrial mass and membrane potential. To investigate the metabolic pathways required for Leishmania amastigotes to persist in BMDMs, we pre-treated cells with small molecule drugs that target major metabolic pathways, revealing that perturbations in several metabolic processes affected parasite survival in a strain-independent manner. Treatments with inhibitors of the oxidative phosphorylation and glycolysis substantially reduced parasite loads. Collectively, our findings suggest that L.amazonensis and L.braziliensis exploit host cell metabolic pathways similarly to survive in macrophages.
Activation Pathways of Murine Macrophages by Lipophosphoglycan from Strains of Leishmania major (FV1 and LV39) Vanessa Mançur Santos, Astrid Madeleine Calero Goicochea, Antônio José Soares Neto, Flávio Henrique Jesus Santos, Jéssica Lobo da Silva, Théo Araújo-Santos, Leonardo Paiva Farias, Claudia Ida Brodskyn, Valéria M. Borges, Rodrigo Pedro Soares, Jonilson Berlink Lima ACS Infectious Diseases, 2024 High Resolution Image Download MS PowerPoint Slide Lipophosphoglycan (LPG) is an important Leishmania virulence factor. It is the most abundant surface glycoconjugate in promastigotes, playing an important role in the interaction with phagocytic cells. While LPG is known to modulate the macrophage immune response during infection, the activation mechanisms triggered by this glycoconjugate have not been fully elucidated. This work investigated the role that LPGs purified from two strains of Leishmania major (FV1 and LV39) play in macrophage activation, considering the differences in their biochemical structures. Bone marrow-derived macrophages from BALB/c mice were stimulated with 10 μg/mL purified LPG from the LV39 and FV1 strains. We then measured the production of nitric oxide (NO) and cytokines, the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), and the activation of MAPK pathways. LPG from the LV39 strain, which has longer poly-galactosylated side chains, induced a more pro-inflammatory profile than that from the FV1 strain. This included higher production of NO, TNF-α, and PGE2, and increased expression of COX-2 and iNOS. Additionally, the phosphorylation of ERK-1/2 and JNK was elevated in macrophages exposed to LPG from the LV39 strain. No difference in IL-10 production was observed in cells stimulated by both LPG. Thus, intraspecific structural differences in LPG contribute to distinct innate immune responses in macrophages.
Intraperitoneal Administration of 17-DMAG as an Effective Treatment against Leishmania braziliensis Infection in BALB/c Mice: A Preclinical Study Kercia P. Cruz, Antonio L. O. A. Petersen, Marina F. Amorim, Alan G. S. F. Pinho, Luana C. Palma, Diana A. S. Dantas, Mariana R. G. Silveira, Carine S. A. Silva, Ana Luiza J. Cordeiro, Izabella G. Oliveira, Gabriella B. Pita, Bianca C. A. Souza, Gilberto C. Bomfim, Cláudia I. Brodskyn, Deborah B. M. Fraga, Isadora S. Lima, Maria B. R. de_Santana, Helena M. P. Teixeira, Juliana P. B. de_Menezes, Washington L. C. Santos, Patrícia S. T. Veras Pathogens, 2024 Background: Leishmaniasis is a significant global public health issue that is caused by parasites from Leishmania genus. With limited treatment options and rising drug resistance, there is a pressing need for new therapeutic approaches. Molecular chaperones, particularly Hsp90, play a crucial role in parasite biology and are emerging as promising targets for drug development. Objective: This study evaluates the efficacy of 17-DMAG in treating BALB/c mice from cutaneous leishmaniasis through in vitro and in vivo approaches. Materials and Methods: We assessed 17-DMAG’s cytotoxic effect on bone marrow-derived macrophages (BMMΦ) and its effects against L. braziliensis promastigotes and intracellular amastigotes. Additionally, we tested the compound’s efficacy in BALB/c mice infected with L. braziliensis via intraperitoneal administration to evaluate the reduction in lesion size and the decrease in parasite load in the ears and lymph nodes of infected animals. Results: 17-DMAG showed selective toxicity [selective index = 432) towards Leishmania amastigotes, causing minimal damage to host cells. The treatment significantly reduced lesion sizes in mice and resulted in parasite clearance from ears and lymph nodes. It also diminished inflammatory responses and reduced the release of pro-inflammatory cytokines (IL-6, IFN-γ, TNF) and the regulatory cytokine IL-10, underscoring its dual leishmanicidal and anti-inflammatory properties. Conclusions: Our findings confirm the potential of 17-DMAG as a viable treatment for cutaneous leishmaniasis and support further research into its mechanisms and potential applications against other infectious diseases.
Pharmacokinetics, Dose-Proportionality, and Tolerability of Intravenous Tanespimycin (17-AAG) in Single and Multiple Doses in Dogs: A Potential Novel Treatment for Canine Visceral Leishmaniasis Marcos Ferrante, Bruna Martins Macedo Leite, Lívia Brito Coelho Fontes, Alice Santos Moreira, Élder Muller Nascimento de Almeida, Claudia Ida Brodskyn, Isadora dos Santos Lima, Washington Luís Conrado dos Santos, Luciano Vasconcellos Pacheco, Vagner Cardoso da Silva, Jeancarlo Pereira dos Anjos, Lílian Lefol Nani Guarieiro, Fabiana Landoni, Juliana P. B. de Menezes, Deborah Bittencourt Mothé Fraga, Aníbal de Freitas Santos Júnior, Patrícia Sampaio Tavares Veras Pharmaceuticals, 2024 In the New World, dogs are considered the main reservoir of visceral leishmaniasis (VL). Due to inefficacies in existing treatments and the lack of an efficient vaccine, dog culling is one of the main strategies used to control disease, making the development of new therapeutic interventions mandatory. We previously showed that Tanespimycin (17-AAG), a Hsp90 inhibitor, demonstrated potential for use in leishmaniasis treatment. The present study aimed to test the safety of 17-AAG in dogs by evaluating plasma pharmacokinetics, dose-proportionality, and the tolerability of 17-AAG in response to a dose-escalation protocol and multiple administrations at a single dose in healthy dogs. Two protocols were used: Study A: four dogs received variable intravenous (IV) doses (50, 100, 150, 200, or 250 mg/m2) of 17-AAG or a placebo (n = 4/dose level), using a cross-over design with a 7-day “wash-out” period; Study B: nine dogs received three IV doses of 150 mg/m2 of 17-AAG administered at 48 h intervals. 17-AAG concentrations were determined by a validated high-performance liquid chromatographic (HPLC) method: linearity (R2 = 0.9964), intra-day precision with a coefficient of variation (CV) ≤ 8%, inter-day precision (CV ≤ 20%), and detection and quantification limits of 12.5 and 25 ng/mL, respectively. In Study A, 17-AAG was generally well tolerated. However, increased levels of liver enzymes–alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT)–and bloody diarrhea were observed in all four dogs receiving the highest dosage of 250 mg/m2. After single doses of 17-AAG (50–250 mg/m2), maximum plasma concentrations (Cmax) ranged between 1405 ± 686 and 9439 ± 991 ng/mL, and the area under the curve (AUC) plotting plasma concentration against time ranged between 1483 ± 694 and 11,902 ± 1962 AUC 0–8 h μg/mL × h, respectively. Cmax and AUC parameters were dose-proportionate between the 50 and 200 mg/m2 doses. Regarding Study B, 17-AAG was found to be well tolerated at multiple doses of 150 mg/m2. Increased levels of liver enzymes–ALT (28.57 ± 4.29 to 173.33 ± 49.56 U/L), AST (27.85 ± 3.80 to 248.20 ± 85.80 U/L), and GGT (1.60 ± 0.06 to 12.70 ± 0.50 U/L)–and bloody diarrhea were observed in only 3/9 of these dogs. After the administration of multiple doses, Cmax and AUC 0–48 h were 5254 ± 2784 μg/mL and 6850 ± 469 μg/mL × h in plasma and 736 ± 294 μg/mL and 7382 ± 1357 μg/mL × h in tissue transudate, respectively. In conclusion, our results demonstrate the potential of 17-AAG in the treatment of CVL, using a regimen of three doses at 150 mg/m2, since it presents the maintenance of high concentrations in subcutaneous interstitial fluid, low toxicity, and reversible hepatotoxicity.
A new experimental model to study shrimp allergy Ivanéia Valeriano Nunes, Camila Mattos Andrade, Priscila Valera Guerra, Mariana Ivo Khouri, Maria Poliana Leite Galantini, Robson Amaro Augusto da Silva, Eliana L. Faquim-Mauro, Leonardo Paiva Farias, Juliana de Souza Rebouças, Ana Maria Caetano Faria, Cláudia Ida Brodskyn Immunology Letters, 2023
Elucidating the role played by bone marrow in visceral leishmaniasis Patricia Sampaio Tavares Veras, Maria Borges Rabêlo de Santana, Claudia Ida Brodskyn, Deborah Bittencourt Mothé Fraga, Manuela Silva Solcà, Juliana Perrone Bezerra De Menezes, Bruna Martins Macedo Leite, Helena Mariana Pitangueira Teixeira Frontiers in Cellular and Infection Microbiology, 2023
Leishmania infantum Defective in Lipophosphoglycan Biosynthesis Interferes With Activation of Human Neutrophils Graziele Quintela-Carvalho, Astrid Madeleine Calero Goicochea, Vanessa Mançur-Santos, Sayonara de Melo Viana, Yasmin da Silva Luz, Beatriz Rocha Simões Dias, Milena Lázaro-Souza, Martha Suarez, Camila Indiani de Oliveira, Elvira M. Saraiva, Cláudia I. Brodskyn, Patrícia T. Veras, Juliana P.B. de Menezes, Bruno B. Andrade, Jonilson Berlink Lima, Albert Descoteaux, Valéria M. Borges Frontiers in Cellular and Infection Microbiology, 2022
COVID-19 vaccine hesitancy and associated factors according to sex: A population-based survey in Salvador, Brazil Nivison Nery, Juan P. Aguilar Ticona, Cristiane W. Cardoso, Ana Paula Pitanga Barbuda Prates, Helena Cristina Alves Vieira, Andrea Salvador de Almeida, Mirela Maisa da Silva Souza, Olivete Borba dos Reis, Maysa Pellizzaro, Moyra Machado Portilho, Renan Rosa da Anunciação, Renato Victoriano, Rosangela Oliveira dos Anjos, Hernán Dario Argibay, Douglas Oliveira Carmo Lima, Isadora Lima Mesquita, Wesley Mota Conceição, Perla Machado Santana, Elaine Carvalho Oliveira, Pamela Santos Nascimento Santana, Claudia Ida Brodskyn, Deborah Bittencourt Mothé Fraga, Manuela da Silva Solcà, Mitermayer Galvão Reis, Federico Costa, Guilherme S. Ribeiro Plos One, 2022
Keratinocytes and activation of trem-1 pathway in cutaneous leishmaniasis lesions Sara Nunes, Mariana Rosa Ampuero, Ícaro Bonyek-Silva, Reinan Lima, Filipe Rocha Lima, Sérgio Marcos Arruda, Ricardo Khouri, Pablo Rafael Silveira Oliveira, Aldina Barral, Viviane Sampaio Boaventura, Cláudia Ida Brodskyn, Natalia Machado Tavares Microbiology Research, 2021
LTB4-driven inflammation and increased expression of ALOX5/ACE2 during severe COVID-19 in individuals with diabetes Icaro Bonyek-Silva, Antônio Fernando Araújo Machado, Thiago Cerqueira-Silva, Sara Nunes, Márcio Rivison Silva Cruz, Jéssica Silva, Reinan Lima Santos, Aldina Barral, Pablo Rafael Silveira Oliveira, Ricardo Khouri, C. Henrique Serezani, Cláudia Brodskyn, Juliana Ribeiro Caldas, Manoel Barral-Netto, Viviane Boaventura, Natalia Machado Tavares Diabetes, 2021
Leukotriene B4 licenses inflammasome activation to enhance skin host defense Ana Carolina Guerta Salina, Stephanie L. Brandt, Nathan Klopfenstein, Amondrea Blackman, Júlia Miranda Ribeiro Bazzano, Anderson Sá-Nunes, Nicole Byers-Glosson, Claudia Brodskyn, Natalia Machado Tavares, Icaro Bonyek Santos Da Silva, Alexandra I. Medeiros, C. Henrique Serezani Proceedings of the National Academy of Sciences of the United States of America, 2020
Lutzomyia longipalpissaliva induces heme oxygenase-1 expression at bite sites Nivea F. Luz, Thiago DeSouza-Vieira, Waldione De Castro, Aislan Carvalho Vivarini, Lais Pereira, Riam Rocha França, Paulo S. Silveira-Mattos, Diego L. Costa, Clarissa Teixeira, Claudio Meneses, Viviane S. Boaventura, Camila I. de Oliveira, Ulisses Gazos Lopes, Naomi Aronson, Bruno B. Andrade, Claudia I. Brodskyn, Jesus G. Valenzuela, Shaden Kamhawi, Valeria M. Borges Frontiers in Immunology, 2018
Plant-feeding phlebotomine sand flies, vectors of leishmaniasis, prefer Cannabis sativa Ibrahim Abbasi, Artur Trancoso Lopo de Queiroz, Oscar David Kirstein, Abdelmajeed Nasereddin, Ben Zion Horwitz, Asrat Hailu, Ikram Salah, Tiago Feitosa Mota, Deborah Bittencourt Mothé Fraga, Patricia Sampaio Tavares Veras, David Poche, Richard Poche, Aidyn Yeszhanov, Cláudia Brodskyn, Zaria Torres-Poche, Alon Warburg Proceedings of the National Academy of Sciences of the United States of America, 2018
Heme drives oxidative stress-associated cell death in human neutrophils infected with Leishmania infantum Graziele Quintela-Carvalho, Nívea F. Luz, Fabiana S. Celes, Dalila L. Zanette, Daniela Andrade, Diego Menezes, Natália M. Tavares, Claudia I. Brodskyn, Deboraci B. Prates, Marilda S. Gonçalves, Camila I. de Oliveira, Roque P. Almeida, Marcelo T. Bozza, Bruno B. Andrade, Valeria M. Borges Frontiers in Immunology, 2017
Proteome Profiling of human cutaneous leishmaniasis lesion Claire da Silva Santos, Sanaz Attarha, Ravi Kanth Saini, Viviane Boaventura, Jackson Costa, Ricardo Khouri, Manoel Barral-Netto, Cláudia Ida Brodskyn, Serhiy Souchelnytskyi Journal of Investigative Dermatology, 2015
Experimental Infection of Dogs with Leishmania and Saliva as a Model to Study Canine Visceral Leishmaniasis Dirceu Joaquim Costa, Rayssa M. de Araujo Carvalho, Melissa Abbehusen, Clarissa Teixeira, Maiana Pitombo, Joelma Trigo, Flávia Nascimento, Lucilene Amorim, Ana Lucia Abreu-Silva, Maria do Socorro Pires Cruz, José Carlos Miranda, Kyoshi Fukutani, Camila I. de Oliveira, Aldina Barral, Manoel Barral-Netto, Cláudia Brodskyn Plos One, 2013
Heme oxygenase-1 promotes the persistence of Leishmania chagasi infection Nívea F Luz, Bruno B Andrade, Daniel F Feijó, Théo Araújo-Santos, Graziele Q Carvalho, Daniela Andrade, Daniel R Abánades, Enaldo V Melo, Angela M Silva, Cláudia I Brodskyn, Manoel Barral-Netto, Aldina Barral, Rodrigo P Soares, Roque P Almeida, Marcelo T Bozza, Valéria M Borges Journal of Immunology, 2012
Lutzomyia longipalpis saliva drives apoptosis and enhances parasite burden in neutrophils Deboraci Brito Prates, Théo Araújo-Santos, Nívea Farias Luz, Bruno B Andrade, Jaqueline França-Costa, Lilian Afonso, Jorge Clarêncio, José Carlos Miranda, Patrícia T Bozza, George A DosReis, Cláudia Brodskyn, Manoel Barral-Netto, Valéria de Matos Borges, Aldina Barral Journal of Leukocyte Biology, 2011
Vaccines for the leishmaniases: Proposals for a research Agenda The Working Group on Research Priorities for Development of Leishmaniasis Vaccines, Carlos Henrique Nery Costa, Nathan C. Peters, Sandra Regina Maruyama, Eldo Cardoso de Brito, Isabel Kinney Ferreira de Miranda Santos Plos Neglected Tropical Diseases, 2011
Searching genes encoding leishmania antigens for diagnosis and protection Manuel Soto, Laura Ramírez, Miguel A. Pineda, Victor M. González, Petter F. Entringer, Camila Indiani de Oliveira, Ivan P. Nascimento, Ana P. Souza, Laura Corvo, Carlos Alonso, Pedro Bonay, Claudia Brodskyn, Aldina Barral, Manoel Barral-Netto, Salvador Iborra Scholarly Research Exchange, 2009
Enhanced Leishmania braziliensis infection following pre-exposure to sandfly saliva Tatiana R. de Moura, Fabiano Oliveira, Fernanda O. Novais, José Carlos Miranda, Jorge Clarêncio, Ivonise Follador, Edgar M. Carvalho, Jesus G. Valenzuela, Manoel Barral-Netto, Aldina Barral, Cláudia Brodskyn, Camila I. de Oliveira Plos Neglected Tropical Diseases, 2007
Short report: Concomitant early mucosal and cutaneous leishmaniasis in Brazil VIVIANE S. BOAVENTURA, VIRGINIA CAFE, JACKSON COSTA, FABIANO OLIVEIRA, ANDRE BAFICA, ANDREA ROSATO, LUIZ A. R. de FREITAS, CLAUDIA BRODSKYN, MANOEL BARRAL-NETTO, ALDINA BARRAL American Journal of Tropical Medicine and Hygiene, 2006
Human_Leishmaniasis@cytokines.bahia.br M. Barral-Netto, C. Brodskyn, E.M. Carvalho, A. Barral Brazilian Journal of Medical and Biological Research, 1998
Comparison between the antigenic composition of bloodstream and cell culture-derived trypomastigotes of Trypanosoma cruzi. Brazilian Journal of Medical and Biological Research Revista Brasileira De Pesquisas Medicas E Biologicas Sociedade Brasileira De Biofisica Et Al, 1988
